Aliases & Classifications for Reading Disorder

Aliases & Descriptions for Reading Disorder:

Name: Reading Disorder 12 14
Developmental Reading Disorder 69
Specific Reading Disorder 69
Dyslexia 69

Classifications:



External Ids:

Disease Ontology 12 DOID:13365
ICD9CM 35 315.09
ICD10 33 F81.0
UMLS 69 C0154631

Summaries for Reading Disorder

Disease Ontology : 12 A learning disability involing difficulty reading resulting primarily from neurological factors which affect any part of the reading process.

MalaCards based summary : Reading Disorder, also known as developmental reading disorder, is related to dyslexia and nephronophthisis 19, and has symptoms including aprosodia An important gene associated with Reading Disorder is KIAA0319 (KIAA0319). The drugs Dopamine and Levodopa have been mentioned in the context of this disorder. Affiliated tissues include brain.

Related Diseases for Reading Disorder

Graphical network of the top 20 diseases related to Reading Disorder:



Diseases related to Reading Disorder

Symptoms & Phenotypes for Reading Disorder

UMLS symptoms related to Reading Disorder:


aprosodia

Drugs & Therapeutics for Reading Disorder

Drugs for Reading Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1068)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 2,Phase 3,Phase 1 51-61-6, 62-31-7 681
2
Levodopa Approved Phase 4,Phase 2,Phase 3 59-92-7 6047
3
Methyltestosterone Approved Phase 4,Phase 3 58-18-4 6010
4
Testosterone Approved, Investigational Phase 4,Phase 3 58-22-0 6013
5
Erythromycin Approved, Vet_approved Phase 4 114-07-8 12560
6
Nifedipine Approved Phase 4,Phase 3 21829-25-4 4485
7
Glycerol Approved, Experimental Phase 4,Early Phase 1 56-81-5 753
8
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2 104987-11-3 445643 439492
9
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 124-94-7 31307
10
Lenograstim Approved Phase 4,Phase 2,Phase 3 135968-09-1
11
Ephedrine Approved Phase 4,Phase 2,Phase 1 299-42-3 9294
12
Pseudoephedrine Approved Phase 4,Phase 2,Phase 1 90-82-4 7028
13
Dorzolamide Approved Phase 4 120279-96-1 3154 5284549
14
Latanoprost Approved, Investigational Phase 4,Phase 3 130209-82-4 5282380 5311221
15
Metformin Approved Phase 4,Phase 3,Phase 2 657-24-9 14219 4091
16
Zinc Approved Phase 4,Phase 3,Phase 2,Phase 1 7440-66-6 32051 23994
17
Menthol Approved Phase 4,Phase 3,Phase 2 2216-51-5 16666
18
Nitric Oxide Approved Phase 4,Phase 3,Phase 1,Phase 2 10102-43-9 145068
19
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
20
Benzocaine Approved Phase 4,Phase 3,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
21
Methotrexate Approved Phase 4,Phase 3,Phase 2 1959-05-2, 59-05-2 126941
22
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
23
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177
24
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
25
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1 174722-31-7 10201696
26
Didanosine Approved Phase 4,Phase 3 69655-05-6 50599
27
Liraglutide Approved Phase 4,Phase 3 204656-20-2
28
Insulin Detemir Approved Phase 4,Phase 3,Phase 2 169148-63-4 5311023
29
Rivaroxaban Approved Phase 4 366789-02-8
30
Ranibizumab Approved Phase 4,Phase 2,Phase 3,Phase 1 347396-82-1 459903
31
Nicotine Approved Phase 4,Phase 2,Phase 3 54-11-5 942 89594
32
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2 53-03-2 5865
33
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 83-43-2 6741
34
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-24-8 5755
35
Ritonavir Approved, Investigational Phase 4,Phase 3,Phase 2 155213-67-5 392622
36
Amphetamine Approved, Illicit Phase 4 300-62-9 5826 3007
37
Guanfacine Approved, Investigational Phase 4,Phase 2 29110-47-2 3519
38
Methylphenidate Approved, Investigational Phase 4,Phase 2 113-45-1 4158
39
Bimatoprost Approved, Investigational Phase 4,Phase 3 155206-00-1 5311027
40
Dinoprost Tromethamine Approved, Vet_approved Phase 4 38562-01-5 5282415
41
Timolol Approved Phase 4,Phase 3 26839-75-8 33624 5478
42
Naproxen Approved, Vet_approved Phase 4,Phase 3,Phase 2 22204-53-1 1302 156391
43
Sumatriptan Approved, Investigational Phase 4 103628-46-2 5358
44
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
45
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
46
Insulin Glargine Approved Phase 4,Phase 3,Phase 2 160337-95-1
47
Insulin Lispro Approved Phase 4,Phase 3,Phase 2 133107-64-9
48
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
49
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 3 58-93-5 3639
50
Norepinephrine Approved Phase 4,Phase 2,Phase 3,Phase 1 51-41-2 439260

Interventional clinical trials:

(show top 50) (show all 2461)
id Name Status NCT ID Phase
1 Dopaminergic Enhancement of Learning and Memory in Healthy Adults and Patients With Dyslexia Unknown status NCT00111371 Phase 4
2 Testosterone Patch's Effects on the Cardiovascular System and Libido Unknown status NCT01208038 Phase 4
3 Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutations in Familial Adenomatous Polyposis Unknown status NCT02175914 Phase 4
4 A Study of Nifecardia SRFC and Adalat OROS in the Treatment of Patients With Essential Hypertension Unknown status NCT00173667 Phase 4
5 Efficacy of Glycerol, Two Topical Steroids, and a Topical Immune Modulator Against Skin Irritation Unknown status NCT00779792 Phase 4
6 Effect of Vitamin D Supplementation on the Control of Asthma in Children at a South African Academic Hospital Unknown status NCT02053402 Phase 4
7 Elmex Gel Efficacy in Preventing White Spot Lesions Unknown status NCT00268138 Phase 4
8 Quaternium-15, Use Test Unknown status NCT00311454 Phase 4
9 Effects on the Diagnostic Accuracy of Magnetic Imaging Angiographies of the Supra-Aortic Vessels by Three Different Magnetic Resonance Contrast Agents in Patients Unknown status NCT00132223 Phase 4
10 Clinical Investigation of the Bi Flex M Multifocal IOL Unknown status NCT02338882 Phase 4
11 The Use of Medical-Expulsive Therapy With Alfuzocine xl 10mg x1/d for Distal Ureterolithiasis.a Randomized Prospective Study Unknown status NCT00489112 Phase 4
12 Filgrastim or Pegfilgrastim in Preventing Neutropenia in Women Receiving Chemotherapy Following Surgery for Breast Cancer Unknown status NCT00030758 Phase 4
13 Comparison of Atomoxetine and Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) and/or Reading Disorder (RD) Completed NCT00191906 Phase 4
14 Effects of Atomoxetine on Brain Activation During Attention and Reading Tasks in Patients With ADHD & Comorbid Dyslexia Completed NCT00716274 Phase 4
15 Interventions for Children With Attention and Reading Disorders Completed NCT01133847 Phase 4
16 Treatment of ADHD With Atomoxetine in Children & Adolescents With ADHD & Comorbid Dyslexia Completed NCT00607919 Phase 4
17 Treatment With Atomoxetine Hydrochloride in Children and Adolescents With ADHD Completed NCT00191048 Phase 4
18 The Effects of Vyvanse(TM) on Brain Hemodynamics and Reading Completed NCT00733356 Phase 4
19 Prostaglandin F2-alpha Eye Drops in Thyroid Eye Disease (Bima Study) Completed NCT02059655 Phase 4
20 Cost-Effectiveness Study Of The Treatment Of Attention Deficit/Hyperactivity Disorder In Brazil Completed NCT01228604 Phase 4
21 Evaluation of the Applicability of the CDEIS to Data Obtained by the Colonic Capsule Endoscopy in Crohn Disease Completed NCT01183845 Phase 4
22 Study of Inhaler Device Attributes Investigating Critical and Overall Errors, Ease of Use, and Preference Between a Number of Inhaler Devices Completed NCT02184624 Phase 4
23 Xenetix® 350: Comparative Assessment of Image Quality for Coronary CT Angiography Completed NCT01255722 Phase 4
24 Evaluation of Reader Training Processes Completed NCT02051790 Phase 4
25 Efficacy Evaluation of Dotarem Compared to Gadovist in the Diagnosis of Peripheral Arterial Disease Completed NCT01026389 Phase 4
26 Omega 3/6 Fatty Acids for Reading in Children Completed NCT02557477 Phase 4
27 The Feasibility of Florbetapir Quantitation in Europe Completed NCT02107599 Phase 4
28 24-hour Efficacy and Ocular Surface With Talfuprost and Triple Combined Therapy Completed NCT02802137 Phase 4
29 Evaluation of the Aspheric ReSTOR IOL After Routine Cataract Extraction Completed NCT00720005 Phase 4
30 Evaluation Of Patient Satisfaction Of Metered Dose Inhaler (MDI) With Counter In Asthmatics And Chronic Obstructive Pulmonary Disease Patients (COPD). Completed NCT00404261 Phase 4
31 The Effects of Long-acting Methylphenidate on Academic Activity and Related Constructs in Children With ADHD Completed NCT02501798 Phase 4
32 Trial of Comprehensive Migraine Intervention Completed NCT01071317 Phase 4
33 Effects of Interactive Video Game Cycling on Obese Adolescent Health Completed NCT00983970 Phase 4
34 The Whole Day First Grade Program Completed NCT00257088 Phase 4
35 A Phase IV Study of Cipro XR in Uncomplicated UTI Completed NCT00663806 Phase 4
36 Making Ramadhan Fasting a Safer Experience With Technology Study Completed NCT02189135 Phase 4
37 FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR) Completed NCT01524705 Phase 4
38 CONCERTA Lab School Study Completed NCT00799487 Phase 4
39 Lab School Day Study for CONCERTA of Older Children With ADHD Completed NCT00799409 Phase 4
40 Bipolar Study in Adults at Least 18 Years of Age Completed NCT00067938 Phase 4
41 Salt Loading and Thiazide Intervention Study Completed NCT00896389 Phase 4
42 Effect of Glycemic Variability on Autonomic Tone in Hospitalized Patients With Type 2 Diabetes Completed NCT01409239 Phase 4
43 Dose Response of Fractional Exhaled Nitric Oxide (FeNO) to Inhaled Steroids in Mild-to-moderate Asthma Completed NCT00995657 Phase 4
44 Open-Label, Randomized Study Evaluating Treatment With Venlafaxine Extended-Release Plus Dialogues Time to Talk Program Completed NCT00401726 Phase 4
45 The Jetstream (JET) Post-market Registry Completed NCT01436435 Phase 4
46 Web-based Smoking Cessation Intervention: Transition From Inpatient to Outpatient Completed NCT01277250 Phase 4
47 Evaluation of Maintaining Visual Performance in Participants Who Engage in Electronic Visual Tasking While Using Restasis® Completed NCT02554981 Phase 4
48 Investigation of Maintaining Visual Performance Achieved With Cyclosporine Therapy Completed NCT02121847 Phase 4
49 CARDS Is Designed To Show If Lowering Cholesterol With Atorvastatin In Type 2 Diabetics Without CV Disease Reduces The Risk Of CV Events Completed NCT00327418 Phase 4
50 Japan Morning Surge-1 Study Completed NCT00285519 Phase 4

Search NIH Clinical Center for Reading Disorder

Genetic Tests for Reading Disorder

Anatomical Context for Reading Disorder

MalaCards organs/tissues related to Reading Disorder:

39
Brain

Publications for Reading Disorder

Articles related to Reading Disorder:

(show all 41)
id Title Authors Year
1
Possible roles for fronto-striatal circuits in reading disorder. ( 27826071 )
2017
2
Descriptive epidemiology of prenatal and perinatal risk factors in a Chinese population with reading disorder. ( 27819320 )
2016
3
Comorbidity of Arithmetic and Reading Disorder: Basic Number Processing and Calculation in Children With Learning Impairments. ( 26772796 )
2016
4
Lifelong Reading Disorder and Mild Cognitive Impairment: Implications for Diagnosis. ( 26639959 )
2015
5
Effectiveness of EEG-Biofeedback on Attentiveness, Working Memory and Quantitative Electroencephalography on Reading Disorder. ( 24644508 )
2013
6
The co-occurrence of reading disorder and ADHD: epidemiology, treatment, psychosocial impact, and economic burden. ( 21757683 )
2012
7
Language Impairments in Children With ADHD and in Children With Reading Disorder. ( 23074303 )
2012
8
Commentary: translating quantitative genetics into molecular genetics: decoupling reading disorder and ADHD - reflections on Greven et al. and Rosenberg et al. (2012). ( 22260725 )
2012
9
Patient characteristics, comorbidities, and medication use for children with ADHD with and without a co-occurring reading disorder: A retrospective cohort study. ( 22145783 )
2011
10
The influence of working memory load on response inhibition in children with attention-deficit/hyperactivity disorder or reading disorder. ( 21432708 )
2011
11
Processing speed and working memory performance in those with both ADHD and a reading disorder compared with those with ADHD alone. ( 21613301 )
2011
12
Tourette syndrome and reading disorder in a boy with left parietofrontal tract disruption. ( 22019420 )
2011
13
Error monitoring in children with ADHD or reading disorder: An event-related potential study. ( 20097256 )
2010
14
Amblyopic dyslexia: a little investigated reading disorder. ( 20401806 )
2010
15
Working memory, response inhibition, and within-subject variability in children with attention-deficit/hyperactivity disorder or reading disorder. ( 19813130 )
2010
16
Evidence for specificity of ERP abnormalities during response inhibition in ADHD children: a comparison with reading disorder children without ADHD. ( 19850394 )
2010
17
Reading disorders in primary progressive aphasia: a behavioral and neuroimaging study. ( 19428421 )
2009
18
Differential effects of atomoxetine on executive functioning and lexical decision in attention-deficit/hyperactivity disorder and reading disorder. ( 20035588 )
2009
19
Expressive versus receptive language skills in specific reading disorder. ( 18415729 )
2008
20
Mismatch negativity (MMN) elicited by duration deviations in children with reading disorder, attention deficit or both. ( 18440662 )
2008
21
Detection of simulated ADHD and reading disorder using symptom validity measures. ( 18534813 )
2008
22
Children with reading disorder show modality independent brain abnormalities during semantic tasks. ( 17010394 )
2007
23
The relationship between attention, executive functions and reading domain abilities in attention deficit hyperactivity disorder and reading disorder: a comparative study. ( 17501726 )
2007
24
Error-related event-related potentials in children with attention-deficit hyperactivity disorder, oppositional defiant disorder, reading disorder, and math disorder. ( 17257731 )
2007
25
Meta-analysis of the nonword reading deficit in specific reading disorder. ( 17009769 )
2006
26
Maternal stress in nonverbal learning disorder: a comparison with reading disorder. ( 16724792 )
2006
27
Electrophysiological and behavioral evidence of auditory processing deficits in children with reading disorder. ( 16564738 )
2006
28
A stimulus-centered reading disorder for words and numbers: Is it neglect dyslexia? ( 16393754 )
2005
29
Spatial-frequency- and contrast-dependent visible persistence and reading disorder: no evidence for a basic perceptual deficit. ( 15206008 )
2004
30
JAMA patient page. Reading disorder. ( 15113824 )
2004
31
Alexia and related reading disorders. ( 12916491 )
2003
32
Varieties of developmental reading disorder: genetic and environmental influences. ( 9927524 )
1999
33
Executive functioning deficits in attention-deficit/hyperactivity disorder are independent of oppositional defiant or reading disorder. ( 10504814 )
1999
34
Language and memory in children with combined complex-partial epilepsy and reading disorder. ( 8323126 )
1993
35
Developmental reading disorder: predictors of outcome in adolescents who received early diagnosis and treatment. ( 1469107 )
1992
36
A comparison of 13-year-old boys with attention deficit and/or reading disorder on neuropsychological measures. ( 2926022 )
1989
37
Language mechanisms and reading disorder: a modular approach. ( 3791919 )
1986
38
EMG and EEG biofeedback training in the treatment of a 10-year-old hyperactive boy with a developmental reading disorder. ( 6882815 )
1983
39
Helping the youngster with a reading disorder. Exploring one problem common to education, psychology, and mental health: summary of a conference. ( 5552374 )
1971
40
Problems in relating visual function to reading disorder. ( 5267181 )
1970
41
Linear dyslexia. A new form of reading disorder. ( 14424629 )
1959

Variations for Reading Disorder

Expression for Reading Disorder

Search GEO for disease gene expression data for Reading Disorder.

Pathways for Reading Disorder

GO Terms for Reading Disorder

Biological processes related to Reading Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 nervous system development GO:0007399 9.46 DCDC2 DNAAF4 KIAA0319 ROBO1
2 neuron migration GO:0001764 9.13 DCDC2 DNAAF4 KIAA0319
3 vocal learning GO:0042297 8.62 CNTNAP2 FOXP2

Sources for Reading Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....